Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Evaluation of health and quality of life in apheresis patients - data from the WAA register.

Goto J, Newman E, Witt V, Deeren D, Blaha M, Lanska M, Gasova Z, Bhuiyan-Ludvikova Z, Hrdlickova R, Ramlow W, Prophet H, Liumbruno G, Griskevicius A, Audzijoniene J, Vrielink H, Aandahl A, Sanchez SO, Strineholm V, Berlin G, Mörtzell-Henriksson M, Stegmayr BG, Eich T, Ilhan O.

Transfus Apher Sci. 2019 Sep 5. pii: S1473-0502(19)30188-0. doi: 10.1016/j.transci.2019.08.024. [Epub ahead of print]

PMID:
31519525
2.

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.

Padmanabhan A, Connelly-Smith L, Aqui N, Balogun RA, Klingel R, Meyer E, Pham HP, Schneiderman J, Witt V, Wu Y, Zantek ND, Dunbar NM, Schwartz GEJ.

J Clin Apher. 2019 Jun;34(3):171-354. doi: 10.1002/jca.21705.

PMID:
31180581
3.

Experience in Rehabilitation Medicine Affects Prognosis and End-of-Life Decision-Making of Neurologists: A Case-Based Survey.

Rogge A, Witt VD, Valdueza JM, Borzikowsky C, Buyx A.

Neurocrit Care. 2019 Aug;31(1):125-134. doi: 10.1007/s12028-018-0661-2.

4.

Post-transplant Replication of Torque Teno Virus in Granulocytes.

Kosulin K, Kernbichler S, Pichler H, Lawitschka A, Geyeregger R, Witt V, Lion T.

Front Microbiol. 2018 Nov 29;9:2956. doi: 10.3389/fmicb.2018.02956. eCollection 2018.

5.

Does prophylactic calcium in apheresis cause more harm than good? - Centre heterogeneity within the World Apheresis Association Register prevents firm conclusions.

Toss F, Edgren G, Berlin G, Stegmayr B, Witt V.

Vox Sang. 2018 Oct;113(7):632-638. doi: 10.1111/vox.12698. Epub 2018 Aug 6.

PMID:
30079964
6.

European Reflections on New Indications for Extracorporeal Photopheresis in Solid Organ Transplantation.

Ahrens N, Geissler EK, Witt V, Berneburg M, Wolff D, Hirt SW, Banas B, Schlitt HJ, Hutchinson JA.

Transplantation. 2018 Aug;102(8):1279-1283. doi: 10.1097/TP.0000000000002244. No abstract available.

PMID:
29664769
7.

Mesoporous silica-based dosage forms improve bioavailability of poorly soluble drugs in pigs: case example fenofibrate.

O'Shea JP, Nagarsekar K, Wieber A, Witt V, Herbert E, O'Driscoll CM, Saal C, Lubda D, Griffin BT, Dressman JB.

J Pharm Pharmacol. 2017 Oct;69(10):1284-1292. doi: 10.1111/jphp.12767. Epub 2017 Jun 20.

PMID:
28631822
8.

Cost-Effectiveness of Defibrotide in the Prophylaxis of Veno-Occlusive Disease after Pediatric Allogeneic Stem Cell Transplantation.

Pichler H, Horner K, Engstler G, Poetschger U, Glogova E, Karlhuber S, Martin M, Eibler W, Witt V, Holter W, Matthes-Martin S.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1128-1133. doi: 10.1016/j.bbmt.2017.03.022. Epub 2017 Mar 27.

9.

Volcanic ash supports a diverse bacterial community in a marine mesocosm.

Witt V, Ayris PM, Damby DE, Cimarelli C, Kueppers U, Dingwell DB, Wörheide G.

Geobiology. 2017 May;15(3):453-463. doi: 10.1111/gbi.12231. Epub 2017 Mar 3.

10.

Changes in hemostasis caused by different replacement fluids and outcome in therapeutic plasma exchange in pediatric patients in a retrospective single center study.

Witt V, Pichler H, Beiglboeck E, Kursten F, Weidner L.

Transfus Apher Sci. 2017 Feb;56(1):59-65. doi: 10.1016/j.transci.2017.01.001. Epub 2017 Jan 19. Review.

PMID:
28188006
11.

Distribution of indications and procedures within the framework of centers participating in the WAA apheresis registry.

Stegmayr B, Mörtzell Henriksson M, Newman E, Witt V, Derfler K, Leitner G, Eloot S, Dhondt A, Deeren D, Rock G, Ptak J, Blaha M, Lanska M, Gasova Z, Bhuiyan-Ludvikova Z, Hrdlickova R, Ramlow W, Prophet H, Liumbruno G, Mori E, Griskevicius A, Audzijoniene J, Vrielink H, Rombout-Sestrienkova E, Aandahl A, Sikole A, Tomaz J, Lalic K, Bojanic I, Strineholm V, Brink B, Berlin G, Dykes J, Toss F, Nilsson T, Knutson F, Ramsauer B, Wahlstrom A.

Transfus Apher Sci. 2017 Feb;56(1):71-74. doi: 10.1016/j.transci.2016.12.023. Epub 2017 Jan 4. Review.

PMID:
28162978
12.

Microparticle detection to guide platelet management for the reduction of platelet refractoriness in children - A study proposal.

Kanzler P, Mahoney A, Leitner G, Witt V, Maurer-Spurej E.

Transfus Apher Sci. 2017 Feb;56(1):39-44. doi: 10.1016/j.transci.2016.12.016. Epub 2016 Dec 29.

PMID:
28089410
13.

Multiple small versus few large amount aspirations for bone marrow harvesting in autologous and allogeneic bone marrow transplantation.

Witt V, Pichler H, Fritsch G, Peters C.

Transfus Apher Sci. 2016 Oct;55(2):221-224. doi: 10.1016/j.transci.2016.07.017. Epub 2016 Jul 16.

PMID:
27452644
14.

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.

Schwartz J, Padmanabhan A, Aqui N, Balogun RA, Connelly-Smith L, Delaney M, Dunbar NM, Witt V, Wu Y, Shaz BH.

J Clin Apher. 2016 Jun;31(3):149-62. doi: 10.1002/jca.21470. Review.

PMID:
27322218
15.

Relevance of flow cytometric enumeration of post-thaw leucocytes: influence of temperature during cell staining on viable cell recovery.

Fritsch G, Frank N, Dmytrus J, Frech C, Pichler H, Witt V, Geyeregger R, Scharner D, Trbojevic D, Zipperer E, Printz D, Worel N.

Vox Sang. 2016 Aug;111(2):187-96. doi: 10.1111/vox.12398. Epub 2016 Apr 1.

PMID:
27037580
16.

Adverse events in apheresis: An update of the WAA registry data.

Mörtzell Henriksson M, Newman E, Witt V, Derfler K, Leitner G, Eloot S, Dhondt A, Deeren D, Rock G, Ptak J, Blaha M, Lanska M, Gasova Z, Hrdlickova R, Ramlow W, Prophet H, Liumbruno G, Mori E, Griskevicius A, Audzijoniene J, Vrielink H, Rombout S, Aandahl A, Sikole A, Tomaz J, Lalic K, Mazic S, Strineholm V, Brink B, Berlin G, Dykes J, Toss F, Axelsson CG, Stegmayr B, Nilsson T, Norda R, Knutson F, Ramsauer B, Wahlström A.

Transfus Apher Sci. 2016 Feb;54(1):2-15. doi: 10.1016/j.transci.2016.01.003. Epub 2016 Jan 8.

17.

Determination of Eligibility in Related Pediatric Hematopoietic Cell Donors: Ethical and Clinical Considerations. Recommendations from a Working Group of the Worldwide Network for Blood and Marrow Transplantation Association.

Bitan M, van Walraven SM, Worel N, Ball LM, Styczynski J, Torrabadella M, Witt V, Shaw BE, Seber A, Yabe H, Greinix HT, Peters C, Gluckman E, Rocha V, Halter J, Pulsipher MA.

Biol Blood Marrow Transplant. 2016 Jan;22(1):96-103. doi: 10.1016/j.bbmt.2015.08.017. Epub 2015 Aug 22. Review.

18.

Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.

Freimüller C, Stemberger J, Artwohl M, Germeroth L, Witt V, Fischer G, Tischer S, Eiz-Vesper B, Knippertz I, Dörrie J, Schaft N, Lion T, Fritsch G, Geyeregger R.

Cytotherapy. 2015 Jul;17(7):989-1007. doi: 10.1016/j.jcyt.2015.03.613. Epub 2015 Apr 9.

PMID:
25866178
19.

Human AdV-specific T cells: persisting in vitro functionality despite lethal irradiation.

Geyeregger R, Freimüller C, Stemberger J, Fischer G, Witt V, Fritsch G.

Bone Marrow Transplant. 2014 Jul;49(7):934-41. doi: 10.1038/bmt.2014.86. Epub 2014 Apr 28.

PMID:
24777182
20.

First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation.

Geyeregger R, Freimüller C, Stemberger J, Artwohl M, Witt V, Lion T, Fischer G, Lawitschka A, Ritter J, Hummel M, Holter W, Fritsch G, Matthes-Martin S.

J Immunother. 2014 May;37(4):245-9. doi: 10.1097/CJI.0000000000000034.

PMID:
24714358
21.

No impact of total or myeloid Cd34+ cell numbers on neutrophil engraftment and transplantation-related mortality after allogeneic pediatric bone marrow transplantation.

Pichler H, Witt V, Winter E, Boztug H, Glogova E, Pötschger U, Matthes-Martin S, Fritsch G.

Biol Blood Marrow Transplant. 2014 May;20(5):676-83. doi: 10.1016/j.bbmt.2014.01.026. Epub 2014 Jan 31.

22.

Erythrocyte-exchange with the OPTIA™ cell separator in patients with sickle-cell disease.

Perseghin P, Incontri A, Capra M, Pichler H, Witt V.

J Clin Apher. 2013 Dec;28(6):411-5. doi: 10.1002/jca.21293. Epub 2013 Sep 2.

PMID:
24000045
23.

Panorama of adverse events during cytapheresis.

Stegmayr B, Ptak J, Nilsson T, Berlin G, Mirea V, Axelsson CG, Griskevicius A, Centoni P, Liumbruno G, Audzijoniene J, Mokvist K, Lassen E, Knutson F, Norda R, Mörtzell M, Prophet H, Ramlow W, Blaha M, Witt V, Efvergren M, Tomaz J, Newman E, Eloot S, Dhondt A, Lalic K, Sikole A, Derfler K, Hrdlickova R, Tomsova H, Gasova Z, Bhuiyan-Ludvikova Z, Ramsauer B, Vrielink H.

Transfus Apher Sci. 2013 Apr;48(2):155-6. doi: 10.1016/j.transci.2013.02.014. Epub 2013 Mar 13. No abstract available.

PMID:
23809812
24.

Robust multi-parameter single-platform quantification of myeloid and B-lymphoid CD34 progenitor cells in all clinical CD34 cell sources and in thawed PBSC.

Fritsch G, Witt V, Spengler HP, Pichler J, Scharner D, Zipperer E, Trbojevic D, Stemberger J, Geyeregger R, Tea MK, Printz D.

Pediatr Hematol Oncol. 2012 Oct;29(7):595-610. Epub 2012 Sep 6.

PMID:
22954345
25.

Terrestrial runoff controls the bacterial community composition of biofilms along a water quality gradient in the Great Barrier Reef.

Witt V, Wild C, Uthicke S.

Appl Environ Microbiol. 2012 Nov;78(21):7786-91. doi: 10.1128/AEM.01623-12. Epub 2012 Aug 17.

26.

Effect of substrate type on bacterial community composition in biofilms from the Great Barrier Reef.

Witt V, Wild C, Uthicke S.

FEMS Microbiol Lett. 2011 Oct;323(2):188-95. doi: 10.1111/j.1574-6968.2011.02374.x. Epub 2011 Aug 24.

27.

Effects of ocean acidification on microbial community composition of, and oxygen fluxes through, biofilms from the Great Barrier Reef.

Witt V, Wild C, Anthony KR, Diaz-Pulido G, Uthicke S.

Environ Microbiol. 2011 Nov;13(11):2976-89. doi: 10.1111/j.1462-2920.2011.02571.x. Epub 2011 Sep 12.

PMID:
21906222
28.

Analyses of data of patients with Thrombotic Microangiopathy in the WAA registry.

Mörtzell M, Berlin G, Nilsson T, Axelsson CG, Efvergren M, Audzijoni J, Griskevicius A, Ptak J, Blaha M, Tomsova H, Liumbruno GM, Centoni P, Newman E, Eloot S, Dhondt A, Tomaz J, Witt V, Rock G, Stegmayr B.

Transfus Apher Sci. 2011 Oct;45(2):125-31. doi: 10.1016/j.transci.2011.07.001. Epub 2011 Sep 7.

PMID:
21903476
29.

Thrombotic microangiopathy.

Mörtzell M, Berlin G, Nilsson T, Axelsson CG, Efvergren M, Audzijoni J, Griskevicius A, Ptak J, Blaha M, Tomsova H, Liumbruno GM, Centoni P, Newman E, Eloot S, Dhondt A, Tomaz J, Witt V, Rock G, Stegmayr B.

Transfus Apher Sci. 2011 Oct;45(2):119-23. doi: 10.1016/j.transci.2011.07.002. Epub 2011 Aug 31.

PMID:
21885345
30.

Assessment of angiogenesis in osseointegration of a silica-collagen biomaterial using 3D-nano-CT.

Alt V, Kögelmaier DV, Lips KS, Witt V, Pacholke S, Heiss C, Kampschulte M, Heinemann S, Hanke T, Thormann U, Schnettler R, Langheinrich AC.

Acta Biomater. 2011 Oct;7(10):3773-9. doi: 10.1016/j.actbio.2011.06.024. Epub 2011 Jun 23. Erratum in: Acta Biomater. 2012 Jan;8(1):457. Thormann, Ulrich [added].

PMID:
21723963
31.

Bone marrow processing with the AMICUS™ separator system.

Witt V, Beiglböck E, Fritsch G.

J Clin Apher. 2011;26(4):195-9. doi: 10.1002/jca.20293. Epub 2011 Jun 27.

PMID:
21710651
32.

Paraproteins of familial MGUS/multiple myeloma target family-typical antigens: hyperphosphorylation of autoantigens is a consistent finding in familial and sporadic MGUS/MM.

Grass S, Preuss KD, Thome S, Weisenburger DD, Witt V, Lynch J, Zettl F, Trümper L, Fadle N, Regitz E, Lynch H, Pfreundschuh M.

Blood. 2011 Jul 21;118(3):635-7. doi: 10.1182/blood-2011-01-331454. Epub 2011 May 17.

33.

Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.

Worel N, Rosskopf K, Neumeister P, Kasparu H, Nachbaur D, Russ G, Namberger K, Witt V, Schloegl E, Zojer N, Linkesch W, Kalhs P, Greinix HT.

Transfusion. 2011 May;51(5):968-75. doi: 10.1111/j.1537-2995.2010.02896.x. Epub 2010 Sep 28.

PMID:
20880037
34.

Novel single-platform multiparameter FCM analysis of apoptosis: Significant differences between wash and no-wash procedure.

Stemberger J, Witt V, Printz D, Geyeregger R, Fritsch G.

Cytometry A. 2010 Nov;77(11):1075-81. doi: 10.1002/cyto.a.20976.

35.

Training courses for pediatric apheresis on site; how apheresis technology transfer can be performed.

Witt V.

Transfus Apher Sci. 2010 Oct;43(2):223-5. doi: 10.1016/j.transci.2010.07.024. Epub 2010 Aug 3.

PMID:
20685167
36.

Granulocyte transfusions in children and young adults: does the dose matter?

Seidel MG, Minkov M, Witt V, Matthes-Martin S, Pötschger U, Worel N, Leitner G, Stary J, Gadner H, Peters C.

J Pediatr Hematol Oncol. 2009 Mar;31(3):166-72. doi: 10.1097/MPH.0b013e318196a6f9.

PMID:
19262241
37.

Detection of human cytomegalovirus-specific T lymphocytes in human blood: comparison of two methods.

Schermann CM, Fischer G, Witt V, Kurz M, Potschger U, Fritsch G.

Cytotherapy. 2008;10(8):834-41. doi: 10.1080/14653240802474315.

PMID:
19016371
38.

World apheresis registry data from 2003 to 2007, the pediatric and adolescent side of the registry.

Witt V, Stegmayr B, Ptak J, Wikström B, Berlin G, Axelsson CG, Griskevicius A, Centoni PE, Liumbruno GM, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Ramlow W, Blaha M, Evergren M, Tomaz J.

Transfus Apher Sci. 2008 Dec;39(3):255-60. doi: 10.1016/j.transci.2008.09.001. Epub 2008 Nov 14.

PMID:
19010084
39.

World apheresis registry 2003-2007 data.

Stegmayr B, Ptak J, Wikström B, Berlin G, Axelsson CG, Griskevicius A, Centoni P, Liumbruno G, Molfettini P, Audzijoniene J, Mokvist K, Sojka BN, Norda R, Knutson F, Ramlow W, Blaha M, Witt V, Evergren M, Tomaz J.

Transfus Apher Sci. 2008 Dec;39(3):247-54. doi: 10.1016/j.transci.2008.09.003. Epub 2008 Oct 31.

PMID:
18977177
40.

Familial myeloma.

Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, Sanger W, Watson P, Nipper H, Witt V, Thomé S.

N Engl J Med. 2008 Jul 10;359(2):152-7. doi: 10.1056/NEJMoa0708704.

41.

Comparative evaluation of techniques for the manufacturing of dendritic cell-based cancer vaccines.

Dohnal AM, Graffi S, Witt V, Eichstill C, Wagner D, Ul-Haq S, Wimmer D, Felzmann T.

J Cell Mol Med. 2009 Jan;13(1):125-35. doi: 10.1111/j.1582-4934.2008.00304.x. Epub 2008 Mar 17.

42.

Performance of a new separator system for routine autologous hematopoietic progenitor cell collection in small children.

Witt V, Beiglböck E, Ritter R, Würth M, Peters C, Ladenstein R, Gadner H, Fritsch G.

J Clin Apher. 2007;22(6):306-13.

PMID:
18080272
43.

Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.

Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C.

Ann Oncol. 2008 Apr;19(4):807-13. Epub 2007 Dec 3.

PMID:
18056650
44.

Phase I study of tumor Ag-loaded IL-12 secreting semi-mature DC for the treatment of pediatric cancer.

Dohnal AM, Witt V, Hügel H, Holter W, Gadner H, Felzmann T.

Cytotherapy. 2007;9(8):755-70. Epub 2007 Oct 4.

PMID:
17917887
45.

Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.

Attarbaschi A, Mann G, Kronberger M, Witt V, Gadner H, Dworzak M.

Klin Padiatr. 2003 Nov-Dec;215(6):321-6.

PMID:
14677096
46.

Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection.

Felzmann T, Witt V, Wimmer D, Ressmann G, Wagner D, Paul P, Hüttner K, Fritsch G.

Cytotherapy. 2003;5(5):391-8.

PMID:
14578101
47.

Collection efficiencies of MNC subpopulations during autologous CD34+ peripheral blood progenitor cell (PBPC) harvests in small children and adolescents.

Witt V, Fischmeister G, Scharner D, Printz D, Pöttschger U, Fritsch G, Gadner H.

J Clin Apher. 2001;16(4):161-8.

PMID:
11835411
48.

Selection of CD34-Positive Blood Cells for Allogeneic Transplantation: Approaches to Optimize D34-Cell Recovery, Purity, Viability, and T-cell Depletion.

Fritsch G, Scharner D, Fröschl G, Buchinger P, Peters C, Matthes S, Witt V, Gadner H.

Onkologie. 2000 Oct;23(5):449-456.

PMID:
11441240
49.

Permanent tunneled silicone central venous catheters for autologous PBPC harvest in children and young adults.

Fischmeister G, Witt V, Zaunschirm HA, Fritsch G, Höcker P, Pötschger U, Zoubek A, Gadner H.

Bone Marrow Transplant. 2000 Oct;26(7):781-6.

50.

Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment.

Peters C, Matthes-Martin S, Fritsch G, Holter W, Lion T, Witt V, Höcker P, Fischer G, Dieckmann K, Handgretinger R, Klingebiel T, Gadner H.

Leukemia. 1999 Dec;13(12):2070-8.

Supplemental Content

Support Center